Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease Differences in Three Siblings with the Same Genotype

Anderson-Fabry disease is a rare X-linked lysosomal storage disease caused by α-galactosidase A (αGalA) gene variants and characterized by a large genotypic and phenotypic spectrum. Enzyme replacement therapy (ERT) using recombinant α-GalA has been approved for > 10 years as a specific therapy for the disease. However, the long-term clinical efficacy for cardiac manifestations has been equivocal because it depends on several factors such as genotype, sex, age, and disease severity at the initiation of ERT. We report the differences in the clinical effects of ERT continued for > 10 years in three patients with the same genotype. Left ventricular hypertrophy and myocardial dysfunction progressed in the heterozygote proband even under ERT, although disease progression was prevented in two sons of Case 1. (Int Heart J 2019; 60: 208-214)

[1]  M. Cubellis,et al.  The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations , 2016, International journal of molecular sciences.

[2]  W. Shimizu,et al.  Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease. , 2016, International heart journal.

[3]  C. Wanner,et al.  Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease , 2016, Nephron.

[4]  M. Beck,et al.  Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment , 2016, Orphanet Journal of Rare Diseases.

[5]  Manesh R. Patel,et al.  Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry , 2016, Journal of Medical Genetics.

[6]  M. Rudnicki,et al.  Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document , 2015, Orphanet Journal of Rare Diseases.

[7]  S. Packman,et al.  Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease , 2015, Journal of Medical Genetics.

[8]  A. Mehta,et al.  Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis , 2015, Molecular genetics and metabolism reports.

[9]  A. Fellgiebel,et al.  Enzyme Replacement Therapy Stabilized White Matter Lesion Progression in Fabry Disease , 2014, Cerebrovascular Diseases.

[10]  F. Pieruzzi,et al.  Intrafamilial phenotypic variability in four families with Anderson‐Fabry disease , 2014, Clinical genetics.

[11]  S. K. White,et al.  Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 Mapping , 2013, Circulation. Cardiovascular imaging.

[12]  P. Elliott,et al.  Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis , 2012, European heart journal.

[13]  D. Warnock,et al.  Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. , 2012, Molecular genetics and metabolism.

[14]  M. Sheppard,et al.  A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. , 2010, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[15]  F. Cecchi,et al.  Cardiovascular events in patients with fabry disease natural history data from the fabry registry. , 2010, Journal of the American College of Cardiology.

[16]  C. Wanner,et al.  Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. , 2008, Molecular genetics and metabolism.

[17]  R. Schiffmann,et al.  Identification of fifteen novel mutations and genotype–phenotype relationship in Fabry disease , 2001, Clinical genetics.

[18]  P. Luna,et al.  [Fabry disease]. , 2009, Anais brasileiros de dermatologia.

[19]  D. Hemelsoet,et al.  Effect of genetic modifiers on cerebral lesions in Fabry disease. , 2006, Neurology.